Spots Global Cancer Trial Database for vactosertib
Every month we try and update this database with for vactosertib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | NCT05400122 | Colorectal Canc... Hematologic Mal... Rectum Cancer Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Chronic Myeloid... Chronic Lymphoc... Hodgkin Lymphom... Non Hodgkin Lym... Myeloproliferat... Plasma Cell Mye... | Vactosertib Fludarabine Pho... Cyclophosphamid... IL-2 Natural Killer ... | 18 Years - | Case Comprehensive Cancer Center | |
| Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma | NCT05588648 | Osteosarcoma | Vactosertib | 14 Years - | MedPacto, Inc. | |
| Vactosertib and Imatinib Combination in Patients With Advanced Desmoid Tumor/Aggressive Fibromatosis (DT/AF) | NCT06219733 | Dermoid | Vactosertib Imatinib | 18 Years - | MedPacto, Inc. | |
| Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma. | NCT04258072 | Pancreas Cancer | Vactosertib | 19 Years - | Samsung Medical Center | |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | NCT05400122 | Colorectal Canc... Hematologic Mal... Rectum Cancer Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Chronic Myeloid... Chronic Lymphoc... Hodgkin Lymphom... Non Hodgkin Lym... Myeloproliferat... Plasma Cell Mye... | Vactosertib Fludarabine Pho... Cyclophosphamid... IL-2 Natural Killer ... | 18 Years - | Case Comprehensive Cancer Center | |
| Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma | NCT06044311 | Adenocarcinoma ... Locally Advance... Siewert Type I ... Siewert Type II... | Vactosertib Standard of Car... Concurrent Radi... | 18 Years - | Case Comprehensive Cancer Center | |
| Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma | NCT03143985 | Multiple Myelom... | Vactosertib Pomalidomide | 18 Years - | Case Comprehensive Cancer Center | |
| As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers | NCT04656002 | Gastric Cancer | Vactosertib | 19 Years - | Samsung Medical Center | |
| Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients | NCT04103645 | Myeloproliferat... | Vactosertib | 18 Years - | Weill Medical College of Cornell University | |
| Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma. | NCT04258072 | Pancreas Cancer | Vactosertib | 19 Years - | Samsung Medical Center | |
| Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases | NCT03844750 | Metastatic Mali... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... | Hepatectomy Pembrolizumab Vactosertib | 18 Years - | University of California, San Francisco | |
| Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma. | NCT04258072 | Pancreas Cancer | Vactosertib | 19 Years - | Samsung Medical Center | |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | NCT05400122 | Colorectal Canc... Hematologic Mal... Rectum Cancer Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Chronic Myeloid... Chronic Lymphoc... Hodgkin Lymphom... Non Hodgkin Lym... Myeloproliferat... Plasma Cell Mye... | Vactosertib Fludarabine Pho... Cyclophosphamid... IL-2 Natural Killer ... | 18 Years - | Case Comprehensive Cancer Center | |
| Vactosertib and Imatinib Combination in Patients With Advanced Desmoid Tumor/Aggressive Fibromatosis (DT/AF) | NCT06219733 | Dermoid | Vactosertib Imatinib | 18 Years - | MedPacto, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
